Page 33 - Robert Kramer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Should you cease and desist? How to respond to international IP litigation 6 minute Read Responding to international intellectual property claims is a legal minefield. Responding, not responding, and even discussing the suit internally can severely affect your likelihood of success. This guide, written by IP expert Robert Kramer, explains why the US is the most likely place you’ll receive a legal letter from, and the nuance involved in responding to the first contact. Not everything is meant to proceed at the speed or informality of the internet. It teaches you: The common methods used to t...

May 28, 2021 10:40am Johnson & Johnson and the FDA have tentatively agreed to release around 60 million Emergent-made COVID-19 vaccine doses, U.S. officials said. (Kruck20/iStock/Getty Images Plus) With production on pause and millions of COVID-19 vaccine doses in limbo, Johnson & Johnson has been hustling to right the ship at CDMO Emergent BioSolutions' troubled Baltimore manufacturing facility. Now, it looks as if relief is in sight. In a matter of days, Johnson & Johnson and the U.S. FDA expect to announce that contamination problems at Emergent's Baltimore plant have been cleared up, pavi...

The Food and Drug Administration and Johnson & Johnson expect to announce that COVID-19 vaccine contamination problems at a facility in Baltimore have been resolved, The Wall Street Journal reported. U.S. officials told the newspaper that emergency use authorization for the Emergent BioSolutions facility to produce J&J's vaccine could come next week. One official told the newspaper Emergent's plant has produced millions of doses but most...

The FDA and Johnson & Johnson (NYSE: JNJ) are expected to announce that contamination problems at Emergent BioSolutions ...

Edenbridge Health announced today that Robert Kramer, a nationally renowned thought leader in senior housing and the care of older adults, has joined its team of advisors. Since its inception in 2016, Edenbridge has gained steady momentum, attracting visionary investors, partners, executives, and advisors.